Kyle Barrett

Senior Data Science Engineer I

Kyle joined Metrum in January 2021 as a Data Science Engineer with research and lab experience in PKPD modeling, biological colloids, and image analysis, including a recent focus on software development, creating tools and automating certain processes using R/R Shiny, C++, and HTML/CSS. His programming experience has involved PBPK and PKPD modeling and simulation and R shiny app development, and he has also modeled anaerobic digestion and created numerous other web apps. Kyle intends to expand his knowledge base in software development and further develop skills in data analysis and visualization.

Recent publications by this scientist

Crowdsourcing Proposal Supporting Patient Engagement in Parkinson’s Disease: A Digital Research Environment (DRE)-Enabled, Patient Swarm Approach to Develop QSP Models

July 23, 2025

Parkinson’s disease remains a complex and poorly understood condition, with critical gaps in our knowledge of disease progression, heterogeneity, and mechanisms of action for existing therapies. To address these challenges, we are launching a collaborative, patient-led effort to develop a QSP model for PD—incorporating real-world patient experiences, clinical insights, and crowdsourced literature review within a secure digital research environment. This initiative aims to accelerate the development of more precise, mechanism-informed therapeutic strategies for the PD community.

Cost Effectiveness of Individualized Dosing for Hypothetical New Drug in Atopic Dermatitis: A Pharmacometric-Pharmacoeconomic Simulation Study

May 27, 2025

A companion poster to the ASCPT print copy, this visual presentation emphasizes the simulation approach used to evaluate individualized dosing strategies and their economic implications. Results underscore the importance of reducing discontinuation rates to enhance value.

Download PDF

Individualized dosing may improve the cost effectiveness of new therapeutics in atopic dermatitis

May 27, 2025

This study uses pharmacometric and pharmacoeconomic modeling to explore the cost effectiveness of individualized dosing for a hypothetical new atopic dermatitis drug compared to dupilumab. Simulation scenarios tested the impact of treatment discontinuation rates, efficacy variability, and pricing on cost utility outcomes.

Download PDF